JESSICA KANTRALES: Open Payments
NPI 1699296145 · MOBILE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,829 in 162 payments from 17 companies in 2025. Trend: 2023 $2,634 · 2024 $3,555 · 2025 $2,829
Food & beverage: $2,720Education: $109
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 37 | $603 |
| Janssen Biotech, Inc. | 27 | $497 |
| Madrigal Pharmaceuticals | 7 | $237 |
| GENZYME CORPORATION | 4 | $222 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 18 | $192 |
| PFIZER INC. | 14 | $182 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $181 |
| Regeneron Healthcare Solutions, Inc. | 8 | $166 |
| Ardelyx, Inc. | 13 | $137 |
| Lilly USA, LLC | 7 | $130 |
Products named: TREMFYA, DUPIXENT, SKYRIZI, RINVOQ, REZDIFFRA, ENTYVIO, IBSRELA, XELJANZ.
Industry payments across AL — which companies pay providers there.
